Literature DB >> 34606331

KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate.

Agnès B Jousset1,2,3,4, Saoussen Oueslati1,3, Cécile Emeraud1,2,3,4, Rémy A Bonnin1,2,3, Laurent Dortet1,2,3,4, Bogdan I Iorga5, Thierry Naas1,2,3,4.   

Abstract

Resistance to the ceftazidime (CAZ)-avibactam (AVI) combination is increasingly being reported. Here, we report a CAZ-AVI-resistant Klebsiella pneumoniae strain belonging to the high-risk sequence type 307 (ST307) clone and producing Klebsiella pneumoniae carbapenemase 39 (KPC-39), a single-amino-acid variant of KPC-3 (A172T). Cloning experiments, steady-state kinetic parameters, and molecular dynamics simulations revealed a loss of carbapenemase activity and increased affinity for CAZ. KPC-39 was identified in a patient without prior exposure to CAZ-AVI, suggesting silent dissemination in European health care settings.

Entities:  

Keywords:  KPC; avibactam resistance; carbapenemase

Mesh：

Substances：

Year:  2021        PMID： 34606331      PMCID： PMC8597731          DOI： 10.1128/AAC.01160-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  29 in total

1.  Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity.

Authors:  Kirk Nelson; Peera Hemarajata; Dongxu Sun; Debora Rubio-Aparicio; Ruslan Tsivkovski; Shangxin Yang; Robert Sebra; Andrew Kasarskis; Hoan Nguyen; Blake M Hanson; Shana Leopold; George Weinstock; Olga Lomovskaya; Romney M Humphries
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

2.  Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity.

Authors:  Saoussen Oueslati; Bogdan I Iorga; Linda Tlili; Cynthia Exilie; Agustin Zavala; Laurent Dortet; Agnès B Jousset; Sandrine Bernabeu; Rémy A Bonnin; Thierry Naas
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

3.  CTX-M-93, a CTX-M variant lacking penicillin hydrolytic activity.

Authors:  Laura Djamdjian; Thierry Naas; Didier Tandé; Gaelle Cuzon; Catherine Hanrotel-Saliou; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

4.  KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam.

Authors:  Vincenzo Di Pilato; Noemi Aiezza; Valentina Viaggi; Alberto Antonelli; Luigi Principe; Tommaso Giani; Francesco Luzzaro; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

5.  Ceftazidime-Avibactam Resistance Associated with Increased bla KPC-3 Gene Copy Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258 Klebsiella pneumoniae.

Authors:  Marco Coppi; Vincenzo Di Pilato; Francesco Monaco; Tommaso Giani; Pier Giulio Conaldi; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 6.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

7.  Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop.

Authors:  Marisa L Winkler; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2015-05-08       Impact factor: 5.790

Review 8.  Emerging Antimicrobial-Resistant High-Risk Klebsiella pneumoniae Clones ST307 and ST147.

Authors:  Gisele Peirano; Liang Chen; Barry N Kreiswirth; Johann D D Pitout
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

9.  Substrate Specificity of OXA-48 after β5-β6 Loop Replacement.

Authors:  Laura Dabos; Agustin Zavala; Rémy A Bonnin; Oliver Beckstein; Pascal Retailleau; Bogdan I Iorga; Thierry Naas
Journal:  ACS Infect Dis       Date:  2020-03-19       Impact factor: 5.084

10.  OmpK36-mediated Carbapenem resistance attenuates ST258 Klebsiella pneumoniae in vivo.

Authors:  Joshua L C Wong; Maria Romano; Louise E Kerry; Hok-Sau Kwong; Wen-Wen Low; Stephen J Brett; Abigail Clements; Konstantinos Beis; Gad Frankel
Journal:  Nat Commun       Date:  2019-09-02       Impact factor: 14.919
View more
  2 in total

Review 1.  Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.

Authors:  Claire Amaris Hobson; Gautier Pierrat; Olivier Tenaillon; Stéphane Bonacorsi; Béatrice Bercot; Ella Jaouen; Hervé Jacquier; André Birgy
Journal:  Antimicrob Agents Chemother       Date:  2022-08-18       Impact factor: 5.938

2.  Extensively Drug-Resistant Klebsiella pneumoniae Counteracts Fitness and Virulence Costs That Accompanied Ceftazidime-Avibactam Resistance Acquisition.

Authors:  Elias Eger; Michael Schwabe; Lukas Schulig; Nils-Olaf Hübner; Jürgen A Bohnert; Uwe T Bornscheuer; Stefan E Heiden; Justus U Müller; Fazal Adnan; Karsten Becker; Carlos L Correa-Martinez; Sebastian Guenther; Evgeny A Idelevich; Daniel Baecker; Katharina Schaufler
Journal:  Microbiol Spectr       Date:  2022-04-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.